EDIT-101 for LCA10 BRILLIANCE trial adult low-dose cohort completed
EDIT-301 for sickle cell disease on track for IND filing by end of 2020
EDIT-201 for solid tumors preclinical data to be presented at SITC and ASH
Cash, cash equivalents, and marketable securities of $541 million as of September 30, 2020
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2020.
We were pleased to regain full operating control of our ocular programs per our new agreement with AbbVie, which provides us with important flexibility. We have finished dosing the first cohort with EDIT-101 in the landmark BRILLIANCE trial and enrollment remains active, said Cynthia Collins, Chief Executive Officer of Editas Medicine.
Ms. Collins continued, The advancements in our ocular portfolio are complemented by the strategic development of our engineered cell medicines. We are on track to file the IND for EDIT-301 for sickle cell disease in the fourth quarter and are eager to present additional data on this potentially best-in-class medicine and our large-scale manufacturing process at the upcoming American Society of Hematology Annual Meeting. Substantial progress has also been made in the development of EDIT-201, an allogeneic NK cell medicine to treat solid tumors. Preclinical data to be presented at ASH show enhanced tumor killing with EDIT-201 compared to unedited NK cells, and additional data on this program will be featured at the upcoming Society for Immunotherapy of Cancers Annual Meeting.
Recent Achievements and Outlook
In VivoCRISPR Medicines
Ex Vivo CRISPR Cell Medicines
Granted Rare Pediatric Disease Designation for treatment of sickle cell diseaseEDIT-301 was granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA). Under the FDAs Rare Pediatric Disease Designation and Voucher programs, a sponsor who receives approval for a drug or biologic for a rare pediatric disease may be eligible for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product.
ASH data to highlight efficient editing with clinical scale manufacturing processPreclinical data to be presented at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH) show CRISPR/Cas12a editing efficiency of the HBG1/2 promoter exceeding 90 percent after long term engraftment in mice of healthy donor hematopoietic stem cells manufactured at clinical scale.
Third Quarter 2020 Financial Results
Cash, cash equivalents, and marketable securities as of September 30, 2020, were $541.3 million, compared to $598.7 million as of June 30, 2020.
For the three months September 30, 2020, net income attributable to common stockholders was $7.8 million, or $0.12 per share, diluted, compared to net loss of $32.9 million, or $0.66 per share, for the same period in 2019.
Editas Medicine plans to participate in the following scientific and medical conferences:
Editas Medicine plans to participate in the following investor events:
The Editas Medicine management team will host a conference call and webcast today at 5:00 p.m. ET to provide and discuss a corporate update and financial results for the third quarter 2020. To access the call, please dial (844) 348-3801 (domestic) or (213) 358-0955 (international) and provide the passcode 9992536.A live webcast of the call will be available on the Investors section of the Editas Medicine website at http://www.editasmedicine.com and a replay will be available approximately two hours after its completion.
About EDIT-101 EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10). EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.
About BRILLIANCE The BRILLIANCE Phase 1/2 clinical trial of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10) is designed to assess the safety, tolerability, and efficacy of EDIT-101 in up to 18 patients with this disorder. Clinical trial sites are enrolling up to five cohorts testing up to three dose levels in this open label, multi-center study. Both adult and pediatric patients (3 17 years old) with a range of baseline visual acuity assessments are eligible for enrollment. Patients receive a single administration of EDIT-101 via subretinal injection in one eye. Additional details are available on http://www.clinicaltrials.gov (NCT#03872479).
About EDIT-201EDIT-201 is an experimental, allogeneic natural killer (NK) cell medicine under investigation for the treatment of solid tumor cancers. EDIT-201 is comprised of NK cells derived from pooled healthy donor blood and genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) to edit the CISH and TGFR2 genes. Editing of the CISH and TGFR2 genes is designed to overcome resistance to therapeutic antibodies and improve NK cell persistence.
About EDIT-301EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease. EDIT-301 is comprised of sickle patient CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) to edit the HBG1/2 promoter region in the beta-globin locus. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin (HbF) production, which has the potential to provide a durable treatment benefit for people living with sickle cell disease.
About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.
Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Companys plans with respect to EDIT-101 and filing an IND for EDIT-301 by the end of 2020. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Companys product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements. Those risks and uncertainties include, among other things, that the Company's expectations regarding the effects of COVID-19 may be incorrect, that data from the Company's development programs may not support registration or further development of its potential medicines due to safety, efficacy or other reasons, and other risks listed under Risk Factors included in the Companys most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
Investor ContactMark Mullikin(617) firstname.lastname@example.org
Media ContactCristi Barnett(617) email@example.com
Read the original:
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 1st, 2020
- Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise - December 1st, 2020
- Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease - News-Medical.Net - December 1st, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 1st, 2020
- Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News - December 1st, 2020
- ONLINE: The UW Now - Isthmus - December 1st, 2020
- Exploring the Challenges and Opportunities of Harvesting CTCs - Technology Networks - December 1st, 2020
- Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire - December 1st, 2020
- Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study - PRNewswire - December 1st, 2020
- COVID-19 patients on some cancer therapies may be contagious for months: study - Reuters - December 1st, 2020
- Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration - GlobeNewswire - December 1st, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - GlobeNewswire - November 30th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 30th, 2020
- Stem Cell Assay Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - Cheshire Media - November 30th, 2020
- Human Embryonic Stem Cell (hESC) Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026 - The Market... - November 30th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - November 30th, 2020
- California's stem cell research agency looks to the future - Bond Buyer - November 26th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 26th, 2020
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 26th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 26th, 2020
- Unexpected discovery about stem cell immortality study - News - The University of Sydney - November 26th, 2020
- 'The hope is that is works': Coliseum participates in clinical trial for COVID-19 recovery - wgxa.tv - November 26th, 2020
- Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots... - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire - November 26th, 2020
- Novel CAR T-cell therapy shows promising early results in children with neuroblastoma - News-Medical.Net - November 26th, 2020
- Our turbulent debates on medicine and morals - The Irish Catholic - November 26th, 2020
- Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,... - November 26th, 2020
- Novartis Invests in Stem Cell Therapy for Covid - BloombergQuint - November 20th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom - November 20th, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 20th, 2020
- In a First, Scientists Say They've Partially Reversed a Cellular Aging Process in Humans - ScienceAlert - November 20th, 2020
- ExCellThera to establish stem cell bioproduction facility creating up to 150 jobs thanks to Government of Canada support - Canada NewsWire - November 16th, 2020
- Stanford coach's quest to save his brother: 'God, I hope this works' - Scope - November 16th, 2020
- Athersys Announces Three Appointments to Board of Directors - Business Wire - November 16th, 2020
- Stem Cell Assay Market Will Generate Massive Revenue In Future: GE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Cell... - November 16th, 2020
- Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic Cancers - Targeted Oncology - November 16th, 2020
- Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology - Newswise - November 16th, 2020
- Stem cell therapy shows promise in treating COVID-19 - The Pharma Letter - November 11th, 2020
- FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform - PRNewswire - November 11th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 11th, 2020
- Global Live Cell Imaging Markets, 2020-2025 - Growing Adoption of High-Content Screening Techniques in Drug Discovery - Yahoo Finance UK - November 11th, 2020
- Protective protein could help keep blood young and healthy - New Atlas - November 10th, 2020
- Worldwide Regenerative Medicine Industry to 2025 - Featuring Allergan, Amgen and Baxter International Among Others - PRNewswire - November 10th, 2020
- Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive - November 8th, 2020
- Global Regenerative Medicine Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com -... - November 8th, 2020
- Using telehealth to boost treatment for substance-use disorder - American Medical Association - November 4th, 2020
- Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 - Aerospace Journal - November 4th, 2020
- Regenerative Medicine Stem Cells Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019 - KYT24 - November 4th, 2020
- Global Stem Cell Assay Market Growth, Size, Analysis, Outlook by 2020 Trends, Opportunities and Forecast to 2025 - Zenit News - November 4th, 2020
- Asia Pacific Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and... - November 4th, 2020
- Asia Pacific Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme ; Application ; End User, and Country -... - November 4th, 2020
- Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan - b3c newswire - November 2nd, 2020
- What Are the Treatment Options When Lymphoma Returns? - SurvivorNet - November 2nd, 2020
- Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market - BioSpace - November 2nd, 2020
- How pain changes your brain - News - The University of Sydney - November 2nd, 2020
- Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View - November 2nd, 2020
- New screening tool could turn up genes tied to developmental disorders - STAT - October 31st, 2020
- Outlook on the Regenerative Medicine Global Market to 2025 - Impact of COVID-19 on the Market - GlobeNewswire - October 31st, 2020
- Opinion: Proposition 14 Could Save the Life of Someone You Love - Times of San Diego - October 31st, 2020
- "Training" the immune system with -glucan compound may improve immune recovery - News-Medical.Net - October 31st, 2020
- Angelika Amon, cell biologist who pioneered research on chromosome imbalance, dies at 53 - MIT News - October 31st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - October 31st, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast... - October 29th, 2020
- Ways to cash in on regenerative medicine - The Australian Financial Review - October 29th, 2020
- We can't stand idly by: Vote 'yes' on Prop. 14 for stem cell research - The Jewish News of Northern California - October 29th, 2020
- Grant programs will provide $2.2 million to support biomedical research on healthy aging - News-Medical.Net - October 29th, 2020
- NK Cell Therapy and Stem Cell Therapy Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth... - October 29th, 2020
- Baby Gets Early Stem Cell Transplant to Treat Rare Disease Thanks to Newborn Screening - University of Michigan Health System News - October 28th, 2020
- Exclusive: "Ending Disease" Documentary Explores How Stem Cell Therapy Aims to Cure the Incurable - Prevention.com - October 28th, 2020
- A New Piece Added to the Pituitary Gland Puzzle Revises Evolutionary History - Technology Networks - October 28th, 2020
- Proposition 14 Aims to Keep California at Worldwide Center of Stem Cell Research - Times of San Diego - October 18th, 2020
- Should California invest $5.5 billion more into promising stem cell research? - The Mercury News - October 14th, 2020
- Singapore invents digitized optimization of culture conditions for cell therapy - BSA bureau - October 14th, 2020
- Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease... - October 14th, 2020
- Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research - Baptist Health South Florida - October 14th, 2020
- Fact check: Trump's antibody therapy not made from fetal stem cells but fetal-derived cells used during testing - USA TODAY - October 12th, 2020
- Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum - October 12th, 2020
- BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa - PRNewswire - October 12th, 2020